Home > Insider Trading > Filing (0000874015-20-000158)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874015	Ionis Pharmaceuticals Inc	IONS	Pharmaceutical Preparations (2834)	330336973

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
897667	T Stanley Crooke	C/O Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010	Exec Chairman Of The Board	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-11-25	12,990	$39.87	15,011	No	4	M	Direct
Common Stock	Disposition	2020-11-25	12,990	$50.05	2,021	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2020-11-25	12,990	$0.00	0	$39.87

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2015-01-02	2021-01-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,581	Indirect	by wife
Common Stock	650,391	Indirect	by Trust

Footnotes

Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019.
Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.85 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.